Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial

Keefe, Richard S. E.; Bilder, Robert M.; Harvey, Philip D.; Davis, Sonia M.; Palmer, Barton W.; Gold, James M.; Meltzer, Herbert Y.; Green, Michael F.; Miller, Del D.; Canive, Jose M.; Adler, Lawrence W.; Manschreck, Theo C.; Swartz, Marvin; Rosenheck, Robert; Perkins, Diana O.; Walker, Trina M.; Stroup, T. Scott; McEvoy, Joseph P.; Lieberman, Jeffrey A.
September 2006
Neuropsychopharmacology;Sep2006, Vol. 31 Issue 9, p2033
Academic Journal
Neurocognition is moderately to severely impaired in patients with schizophrenia. However, the factor structure of the various neurocognitive deficits, the relationship with symptoms and other variables, and the minimum amount of testing required to determine an adequate composite score has not been determined in typical patients with schizophrenia. An ‘all-comer’ approach to cognition is needed, as provided by the baseline assessment of an unprecedented number of patients in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) schizophrenia trial. From academic sites and treatment providers representative of the community, 1493 patients with chronic schizophrenia were entered into the study, including those with medical comorbidity and substance abuse. Eleven neurocognitive tests were administered, resulting in 24 individual scores reduced to nine neurocognitive outcome measures, five domain scores and a composite score. Despite minimal screening procedures, 91.2% of patients provided meaningful neurocognitive data. Exploratory principal components analysis yielded one factor accounting for 45% of the test variance. Confirmatory factor analysis showed that a single-factor model comprised of five domain scores was the best fit. The correlations among the factors were medium to high, and scores on individual factors were very highly correlated with the single composite score. Neurocognitive deficits were modestly correlated with negative symptom severity (r=0.13–0.27), but correlations with positive symptom severity were near zero (r<0.08). Even in an ‘all-comer’ clinical trial, neurocognitive deficits can be assessed in the overwhelming majority of patients, and the severity of impairment is similar to meta-analytic estimates. Multiple analyses suggested that a broad cognitive deficit characterizes this sample. These deficits are modestly related to negative symptoms and essentially independent of positive symptom severity.Neuropsychopharmacology (2006) 31, 2033–2046. doi:10.1038/sj.npp.1301072; published online 19 April 2006


Related Articles

  • Cognitive remediation therapy in schizophrenia. Wykes, Til; Reeder, Clare; Landau, Sabine; Everitt, Brian; Knapp, Martin; Patel, Anita; Romeo, Renee // British Journal of Psychiatry;May2007, Vol. 190, p421 

    Background Cognitive difficulties are prevalent in people with a diagnosis of schizophrenia and are associated with poor long-term functioning. Aims To evaluate the effectiveness of cognitive remediation therapy on cognitive difficulties experienced by people with schizophrenia. Method...

  • Kafka, paranoic doubles and the brain: hypnagogic vs. hyper-reflexive models of disrupted self in neuropsychiatric disorders and anomalous conscious states. Mishara, Aaron L. // Philosophy, Ethics & Humanities in Medicine;2010, Vol. 5, p13 

    Kafka's writings are frequently interpreted as representing the historical period of modernism in which he was writing. Little attention has been paid, however, to the possibility that his writings may reflect neural mechanisms in the processing of self during hypnagogic (i.e., between waking...

  • Progress Towards Validating the NMDA Receptor Hypofunction Hypothesis of Schizophrenia. Lindsley, Craig W.; Shipe, William D.; Wolkenberg, Scott E.; Theberge, Cory R.; Williams Jr., David L.; Sur, Cyrille; Kinney, Gene G. // Current Topics in Medicinal Chemistry;Apr2006, Vol. 6 Issue 8, p771 

    This article describes recent progress towards validation of the N-methyl-D-aspartate (NMDA) receptor hypofunction hypothesis of schizophrenia in preclinical models. Schizophrenia, a complex disease characterized by positive, negative and cognitive symptoms, affects 1% of the world population...

  • Down with schizophrenia. Kingdon, David // New Scientist;10/13/2007, Vol. 196 Issue 2625, p22 

    The author reports that the term schizophrenia may stop being used as a classification of psychiatric disorders starting in 2011. Problems which medical professionals have had in regards to diagnosing patients with schizophrenia are mentioned. According to the article, psychiatry professionals...

  • Patterns of neurocognitive impairment in first-episode bipolar disorder and schizophrenia. Barrett, Suzanne L.; Mulholland, Ciaran C.; Cooper, Stephen J.; Rushe, Teresa M. // British Journal of Psychiatry;Jul2009, Vol. 195 Issue 1, p67 

    Background: Researching psychotic disorders in unison rather than as separate diagnostic groups is widely advocated, but the viability of such an approach requires careful consideration from a neurocognitive perspective.Aims: To describe cognition in people with bipolar...

  • WHEN DOES COGNITIVE DECLINE OCCUR in the Period Prior to the First Episode of Schizophrenia? Harvey, Philip D. // Psychiatry (1550-5952);Jul2009, Vol. 6 Issue 7, p12 

    Cognitive impairment is common in people with schizophrenia. These impairments are detectable prior to any signs of illness in people who are destined to develop the disease and they are as severe at the time of the first psychotic episode as they are after many years of illness. It was formerly...

  • Déjà vu experiences and reduplicative paramnesia. Sno, Herman N.; Linszen, Don H.; De Jonghe, Frans; Sno, H N; Linszen, D H; de Jonghe, F // British Journal of Psychiatry;Oct92, Vol. 161, p565 

    A schizophrenic patient with different forms of experiences of inappropriate familiarity is described. The authors discuss traumatic experiences as aetiological factors in déjà vu experiences and reduplicative paramnesia. Finally, the differential diagnostic problem in psychotic and...

  • Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Morice, Rodney; Morice, R // British Journal of Psychiatry;Jul90, Vol. 157, p50 

    The ability to shift cognitive set, which is probably subserved, at least in part, by the pre-frontal cortex, was determined for schizophrenic, bipolar (manic) and control subjects, using the Wisconsin Card Sorting Test (WCST). The schizophrenic and manic subjects both demonstrated poor...

  • Short Cognitive Performance Test: Diagnostic Accuracy and Education Bias in Older Brazilian Adults. Flaks, Mariana K.; Forlenza, Orestes V.; Pereira, Fernanda S.; Viola, Luciane F.; Yassuda, Mônica S. // Archives of Clinical Neuropsychology;May2009, Vol. 24 Issue 3, p301 

    The “Short Cognitive Performance Test” (Syndrom Kurztest, SKT) is a cognitive screening battery designed to detect memory and attention deficits. The aim of this study was to evaluate the diagnostic accuracy of the SKT as a screening tool for mild cognitive impairment (MCI) and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics